Kristof Prinsen
Katholieke Universiteit Leuven
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Kristof Prinsen.
Radiology | 2011
Junjie Li; Ziping Sun; Jian Zhang; Haibo Shao; Marlein Miranda Cona; Huaijun Wang; Thierry Marysael; Feng Chen; Kristof Prinsen; Lin Zhou; Dejian Huang; Johan Nuyts; Jie Yu; Bin Meng; Guy Bormans; Zhijun Fang; Peter de Witte; Yaming Li; Alfons Verbruggen; Xiaoning Wang; Luc Mortelmans; Ke Xu; Guy Marchal; Yicheng Ni
PURPOSE To test the hypothesis that targeting the microenvironment (soil) may effectively kill cancer cells (seeds) through a small-molecular weight sequential dual-targeting theragnostic strategy, or dual-targeting approach. MATERIALS AND METHODS With approval from the institutional animal care and use committee, 24 rats were implanted with 48 liver rhabdomyosarcomas (R1). First, the vascular-disrupting agent combretastatin A4 phosphate (CA4P) was injected at a dose of 10 mg/kg to cause tumor necrosis, which became a secondary target. Then, the necrosis-avid agent hypericin was radiolabeled with iodine 131 to form (131)I-hypericin, which was injected at 300 MBq/kg 24 hours after injection of CA4P. Both molecules have small molecular weight, are naturally or synthetically derivable, are intravenously injectable, and are of unique targetablities. The tumor response in the dual-targeting group was compared with that in vehicle-control and single-targeting (CA4P or (131)I-hypericin) groups with in vivo magnetic resonance imaging and scintigrams and ex vivo gamma counting, autoradiography, and histologic analysis. Tumor volumes, tumor doubling time (TDT), and radiobiodistribution were analyzed with statistical software. P values below .05 were considered to indicate a significant difference. RESULTS Eight days after treatment, the tumor volume of rhabdomyosarcoma in the vehicle-control group was double that in both single-targeting groups (P < .001) and was five times that in the dual-targeting group (P < .0001), without treatment-related animal death. The TDT was significantly longer in the dual-targeting group (P < .0001). Necrosis appeared as hot spots on scintigrams, corresponding to 3.13% of the injected dose of (131)I-hypericin per gram of tissue (interquartile range, 2.92%-3.97%) and a target-to-liver ratio of 20. The dose was estimated to be 100 times the cumulative dose of 50 Gy needed for radiotherapeutic response. Thus, accumulated (131)I-hypericin from CA4P-induced necrosis killed residual cancer cells with ionizing radiation and inhibited tumor regrowth. CONCLUSION This dual-targeting approach may be a simple and workable solution for cancer treatment and deserves further exploitation.
Bioorganic & Medicinal Chemistry Letters | 2013
Kristof Prinsen; Marlein Miranda Cona; Jan Cleynhens; H Vanbilloen; Junjie Li; Natalia Dyubankova; Eveline Lescrinier; Guy Bormans; Yicheng Ni; Alfons Verbruggen
The aim of the present study was to develop a (68)Ga labeled bis-DOTA derivative of benzylidene-bis-indole and compare the in vivo stability and biodistribution with that of the previously reported bis-DTPA derivate for in vivo imaging of necrosis using PET. Uptake of the tracer was evaluated in a mouse model of Fas-mediated hepatic apoptosis in correlation with histochemical stainings. The novel (68)Ga labeled tracer showed an improved in vivo stability and could therefore be used for selective non-invasive imaging of necrotic cell death using PET.
Methods | 2009
Marijke De Saint-Hubert; Kristof Prinsen; Luc Mortelmans; Alfons Verbruggen; Felix M. Mottaghy
Bioorganic & Medicinal Chemistry | 2010
Marijke De Saint-Hubert; Felix M. Mottaghy; Kathleen Vunckx; Johan Nuyts; Humphrey Fonge; Kristof Prinsen; Sigrid Stroobants; Luc Mortelmans; Niko Deckers; Leo Hofstra; Chris Reutelingsperger; Alfons Verbruggen; Dirk Rattat
Bioorganic & Medicinal Chemistry | 2010
Kristof Prinsen; Junjie Li; H Vanbilloen; Peter Vermaelen; Ellen Devos; Luc Mortelmans; Guy Bormans; Yicheng Ni; Alfons Verbruggen
Bioconjugate Chemistry | 2007
Humphrey Fonge; Satish K. Chitneni; Jin Lixin; Kathleen Vunckx; Kristof Prinsen; Johan Nuyts; Luc Mortelmans; Guy Bormans; Yicheng Ni; Alfons Verbruggen
Bioorganic & Medicinal Chemistry Letters | 2011
Kristof Prinsen; Lixin Jin; Kathleen Vunckx; Marijke De Saint-Hubert; Lin Zhou; Jan Cleynhens; Johan Nuyts; Guy Bormans; Yicheng Ni; Alfons Verbruggen
Nuclear Medicine and Biology | 2013
Kristof Prinsen; Marlein Miranda Cona; Bernard Cleynhens; Junjie Li; H Vanbilloen; Natalia Dyubankova; Eveline Lescrinier; Yicheng Ni; Guy Bormans; Alfons Verbruggen
Society of Nuclear Medicine Annual Meeting Abstracts | 2009
Marijke De Saint-Hubert; Kristof Prinsen; Johan Nuyts; Kathleen Vunckx; Lin Zhou; Dirk Rattat; Luc Mortelmans; Chris Reutelingsperger; Alfons Verbruggen; Felix M. Mottaghy
Contrast Media Research Meeting 2009 | 2009
Yicheng Ni; Junjie Li; Marlein Miranda Cona; Feng Chen; Huaijun Wang; Thierry Marysael; Peter de Witte; Kristof Prinsen; Alfons Verbruggen; Guy Bormans; Lin Zhou; Johan Nuyts; Guy Marchal; Jian Zhang; Ziping Sun